Genovis AB (publ.) (STO:GENO)

Market Cap	1.32B -16.2%
Revenue (ttm)	135.89M +11.2%
Net Income	20.50M -24.0%
EPS	0.31 -24.8%
Shares Out	67.46M
PE Ratio	63.11
Forward PE	47.95
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,631
Open	19.30
Previous Close	19.54
Day's Range	19.30 - 20.10
52-Week Range	15.64 - 24.50
Beta	1.76
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 10, 2026

About Genovis AB (publ.)

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisRE...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 42
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: GENO

Financial Performance

In 2025, Genovis AB (publ.)'s revenue was 129.23 million, a decrease of -1.06% compared to the previous year's 130.61 million. Earnings were 23.50 million, a decrease of -28.61%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 5, 2026

Data Sources Report a data error